Abstract
The National Institutes of Health's National Institute of General Medical Sciences (NIGMS) is about to issue a program announcement aimed at increasing the proportion of high-risk, potentially high-payoff biomedical research that it supports. This initiative is one of the several ways that NIGMS, under its new director, biochemist Marvin Cassman, is attempting to strike a balance in its research portfolio with the intention of maximizing return for the U.S. research enterprise. It's actually hard to call Cassman the new'' director of NIGMS. After nearly 21 years at the institute and three years as its acting director, he's a seasoned veteran despite his mere two months officially in the position. NIGMS, with the fourth largest budget of the institutes at NIH, is in the business of supporting basic biomedical research that is not targeted to specific diseases or disorders. Cassman oversees a budget of approximately $1 billion, nearly 80% of which funds basic research in ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
